

Development of SOTP™ Model for Evaluating Therapeutics Against Spread of Tau Pathology

 Oligomerix, Inc.

D. R. Patel, P. Lopez, K. Callahan, E. J. Davidowitz, and J. G. Moe. Oligomerix, Inc., Bronx, NY, USA

 ALZHEIMER'S ASSOCIATION

AAIC>26


#13162

BACKGROUND

Alzheimer’s disease progression is driven by Tau accumulation and spread.

Human-relevant in vivo models remain limited.

Oligomerix developed the SOTP™ model by injecting human AD-derived tau seeds that are either high molecular weight oligomers (HMW) or sarkosyl-insoluble (SRK) tau species into humanized tau knock-in mice (MAPT(H1.0)-GR; JAX:035398; Benzow et al., 2024).



Left panel - showing stereotaxic coordinates (ML 1.5 mm, AP -2.4 mm, DV -1.6 mm; red dot), with induction site for local pathology in hippocampus at CA1 region (orange) and downstream spread to CA3 region and entorhinal cortex (green/blue) (adapted from Paxinos and Franklin, 2001).

Right panel – 3-month mouse brain injected with methylene blue and regions analyzed for induction and spread of tau pathology. Hippocampal CA1 and CA3 regions and entorhinal cortex .

Methods adapted from Mate De Gerando et al., 2023.

